pharma
Glenmark Pharmaceuticals
GLENMARK · Nifty 50
₹2,136.6
Price 2026-06-17
At a Glance
Fundamental
100/100
STRONG
Trust
95/100
Verification
Coverage
44/100
LIMITED
Quick Take
Glenmark Pharmaceuticals scores 100/100 on fundamentals (strong). Glenmark Pharmaceuticals: BROAD EXPANSION regime.
Fundamental Score: 100/100 · STRONG · 2 signals detected
DuPont Analysis
ROE 13.0% broken into three drivers. Each shows how efficiently the company generates returns.
ROE of 12.96% is moderate efficiency-driven and stable. Net margin of 8.2% × asset turnover of 0.84x × leverage of 1.9x.
What This Means
Net margin of 8.2% means the company keeps ₹8.2 as profit for every ₹100 of revenue. This is a moderate-margin business. Asset turnover of 0.84x means the company efficiently uses its assets to generate revenue. Leverage of 1.9x means the company uses moderate debt. Returns are primarily driven by operations, not borrowing.
Margin Structure
Gross
71.6%
Operating
13.1%
Net
8.2%
Gross margin 71.6% → operating margin 13.1% → net margin 8.2%. Margins are DECLINING. Check if input costs are rising or competition is pressuring pricing.
Financial Health
Earnings Quality
STRONGCash flow covers net income 2.5x — earnings are HIGH QUALITY. The company converts profit to cash efficiently.
Debt Sustainability
COMFORTABLEInterest covered 10.5x — very comfortable. Debt service is not a concern. Debt/EBITDA at 0.2x is low — balance sheet has capacity.
Free Cash Flow
STRONGFCF margin at 12.5% — strong cash generation. Business is self-funding.
Peer Comparison
Glenmark Pharmaceuticals is compared against 10 peers in the pharma sector.
Key Watchpoints
Breaks above ₹2243 (+5%)
Trend reversal confirmation
Breaks below ₹2030 (-5%)
Further downside risk
Pharma sector entering leadership
Sector rotation signal
Detected Patterns
Risk Flags
One-off items significantly inflating reported profit. Core earnings may be much lower.
Liquidity squeeze. Company may struggle to meet short-term obligations without refinancing.
Special charges of ₹2266K Cr. May indicate restructuring, impairment, or one-time costs.
Elevated risk score. Review audit, board, and shareholder rights metrics.
Collection cycle changing. Collection improving — positive for cash flow.
🔴 2 CRITICAL flags — significant concerns. Investigate before investing.
Data Quality
News Correlation
50 articles scanned for fundamental themes